*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

BI 1703880 is currently being investigated in a Phase I trial as a combination with ezabenlimab (BI 754091),* a PD-1 inhibitor, in patients with advanced solid tumors.²

STING agonist (BI 1703880) clinical trial

STING agonist mechanism of action

STING functions as a DNA sensor and is expressed in immune cells, stromal cells and tumor cells.

STING pathway activation by STING agonist induces the production of Type I interferon (IFN) and inflammatory cytokine secretion in the tumor microenvironment (TME), leading to innate immune cell activation, cross-priming, activation, and infiltration of cytotoxic T-cells, and subsequent tumor cell killing.^1,3

Immuno-modulatory mechanism of action¹

cGAS, cyclic GMP–AMP synthase; IFN, interferon; PD-1, programmed cell death protein-1; STING, stimulator of interferon genes; TME, tumor microenvironment.